Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Fluorescent Gene Tagging of Transcriptionally Silent Genes in hiPSCs.

Roberts B, Hendershott MC, Arakaki J, Gerbin KA, Malik H, Nelson A, Gehring J, Hookway C, Ludmann SA, Yang R, Haupt A, Grancharova T, Valencia V, Fuqua MA, Tucker A, Rafelski SM, Gunawardane RN.

Stem Cell Reports. 2019 May 14;12(5):1145-1158. doi: 10.1016/j.stemcr.2019.03.001. Epub 2019 Apr 4.

2.

Endogenous Protein Tagging in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.

Haupt A, Grancharova T, Arakaki J, Fuqua MA, Roberts B, Gunawardane RN.

J Vis Exp. 2018 Aug 25;(138). doi: 10.3791/58130.

3.

Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization.

Roberts B, Haupt A, Tucker A, Grancharova T, Arakaki J, Fuqua MA, Nelson A, Hookway C, Ludmann SA, Mueller IA, Yang R, Horwitz R, Rafelski SM, Gunawardane RN.

Mol Biol Cell. 2017 Oct 15;28(21):2854-2874. doi: 10.1091/mbc.E17-03-0209. Epub 2017 Aug 16.

4.

Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism.

Gunawardane RN, Fordstrom P, Piper DE, Masterman S, Siu S, Liu D, Brown M, Lu M, Tang J, Zhang R, Cheng J, Gates A, Meininger D, Chan J, Carlson T, Walker N, Schwarz M, Delaney J, Zhou M.

J Biol Chem. 2016 Feb 5;291(6):2799-811. doi: 10.1074/jbc.M115.672790. Epub 2015 Dec 7.

5.

The high-resolution crystal structure of human LCAT.

Piper DE, Romanow WG, Gunawardane RN, Fordstrom P, Masterman S, Pan O, Thibault ST, Zhang R, Meininger D, Schwarz M, Wang Z, King C, Zhou M, Walker NP.

J Lipid Res. 2015 Sep;56(9):1711-9. doi: 10.1194/jlr.M059873. Epub 2015 Jul 20.

6.

PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.

Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS.

Cancer Cell. 2013 Jun 10;23(6):753-67. doi: 10.1016/j.ccr.2013.04.026.

7.

Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.

Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, Armstrong RC.

Mol Cancer Ther. 2013 Apr;12(4):438-47. doi: 10.1158/1535-7163.MCT-12-0305. Epub 2013 Feb 14.

8.

Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.

Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, Gardner MF, James J, Breider MA, Belli B, Armstrong RC, Treiber DK.

J Med Chem. 2012 Apr 12;55(7):3250-60. doi: 10.1021/jm201702g. Epub 2012 Mar 14.

PMID:
22380736
9.

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.

James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW.

Mol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.

10.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, Valenta I, Hua H, Gardner MF, Cramer MD, Gitnick D, Insko DE, Apuy JL, Jones-Bolin S, Ghose AK, Herbertz T, Ator MA, Dorsey BD, Ruggeri B, Williams M, Bhagwat S, James J, Holladay MW.

J Med Chem. 2012 Feb 9;55(3):1082-105. doi: 10.1021/jm2009925. Epub 2012 Jan 23.

PMID:
22168626
11.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Holladay MW, Campbell BT, Rowbottom MW, Chao Q, Sprankle KG, Lai AG, Abraham S, Setti E, Faraoni R, Tran L, Armstrong RC, Gunawardane RN, Gardner MF, Cramer MD, Gitnick D, Ator MA, Dorsey BD, Ruggeri BR, Williams M, Bhagwat SS, James J.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5342-6. doi: 10.1016/j.bmcl.2011.07.019. Epub 2011 Jul 14.

PMID:
21807507
12.

MYC regulation of a "poor-prognosis" metastatic cancer cell state.

Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703. doi: 10.1073/pnas.0914203107. Epub 2010 Feb 4.

13.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS.

J Med Chem. 2009 Dec 10;52(23):7808-16. doi: 10.1021/jm9007533.

PMID:
19754199
14.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.

15.

Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer.

Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, Taron B, Isakoff SJ, Brugge JS, LaBaer J.

J Proteome Res. 2006 Mar;5(3):599-610.

16.

Novel role for PDEF in epithelial cell migration and invasion.

Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS.

Cancer Res. 2005 Dec 15;65(24):11572-80.

17.

Characterization of a new gammaTuRC subunit with WD repeats.

Gunawardane RN, Martin OC, Zheng Y.

Mol Biol Cell. 2003 Mar;14(3):1017-26.

18.

Purification and reconstitution of Drosophila gamma-tubulin complexes.

Gunawardane RN, Zheng Y, Oegema K, Wiese C.

Methods Cell Biol. 2001;67:1-25. No abstract available.

PMID:
11550462
19.

Characterization and reconstitution of Drosophila gamma-tubulin ring complex subunits.

Gunawardane RN, Martin OC, Cao K, Zhang L, Dej K, Iwamatsu A, Zheng Y.

J Cell Biol. 2000 Dec 25;151(7):1513-24.

20.

gamma-Tubulin complexes and their role in microtubule nucleation.

Gunawardane RN, Lizarraga SB, Wiese C, Wilde A, Zheng Y.

Curr Top Dev Biol. 2000;49:55-73. Review. No abstract available.

PMID:
11005014
21.

Supplemental Content

Loading ...
Support Center